Skip to main content
S&P 5007,772.18-0.60%DOW50,992.80-1.03%NASDAQ27,400.23-0.72%BTC$83,189.00-3.49%ETH$2,567.06-5.34%GOLD$4,125.30-1.48%OIL$90.21+0.86%
Smart Investors Daily
SID Premium
RC

NASDAQ · RCEL

AVITA Medical, Inc.

Healthcare · Medical - Devices

$12.99

Down-$0.00 (-0.03%)

Updated Oct 7, 2026, 2:14 PM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
94.53M
P/E ratio
-1.8
Dividend yield
0.00%
52-week range
$3.22 – $13.48
Volume
409.88K
Avg. volume
574.48K

Price performance · RCEL

RCEL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

RCEL closed at $12.99 after 21 trading sessions, up 24.78% for the selected period.

Last close
$12.99
Period change
+24.78%
Period low
$9.86
Period high
$13.25
Daily close
View OHLC price history
RCEL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$13.38$13.495$12.39$12.99409.88K
Oct 5, 2026$12.64$13.48$12.5341$13.25420.76K
Oct 2, 2026$12.07$12.76$12.02$12.72391.21K
Oct 1, 2026$11.77$12.40$11.73$12.01496.54K
Sep 30, 2026$11.90$12.12$11.60$11.73249.74K
Sep 29, 2026$11.73$12.11$11.63$11.96253.61K
Sep 28, 2026$11.63$11.755$11.3367$11.67208.13K
Sep 25, 2026$11.64$12.23$11.56$11.84341.49K
Sep 24, 2026$10.95$11.76$10.905$11.58420.54K
Sep 23, 2026$11.49$11.68$10.87$10.95237.26K
Sep 22, 2026$10.86$11.81$10.71$11.49528.41K
Sep 21, 2026$11.04$11.04$10.61$10.84194.68K
Sep 18, 2026$11.15$11.195$10.72$11.02359.08K
Sep 17, 2026$10.65$11.25$10.53$11.22371.59K
Sep 16, 2026$10.15$10.67$10.09$10.45311.33K
Sep 15, 2026$10.11$10.2995$9.90$10.21181.66K
Sep 14, 2026$9.87$10.4579$9.755$10.19333.4K
Sep 11, 2026$10.05$10.06$9.60$9.88225.24K
Sep 10, 2026$10.00$10.34$9.80$9.86245.4K
Sep 9, 2026$10.32$10.495$10.11$10.16154.5K
Sep 8, 2026$11.23$11.23$10.33$10.41312.05K

Latest RCEL news

The latest Smart Investors Daily articles mentioning RCEL.

Stock researchCompany · Overview

RCEL research

Overview

Company profile and research snapshot.

Company profile

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
RCEL recent ratings
DateFirmRatingTarget
Aug 28, 2026Lake StreetBuy—
Aug 19, 2026BTIGBuy—
Aug 19, 2026TD CowenBuy—
Aug 7, 2026BTIGBuy—
May 15, 2026Lake StreetBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 25, 2026

AVITA Medical (RCEL) Stock Fair Value Rises After PermeaDerm Data And Analyst Target Increases

AVITA Medical is back in focus after fair value estimates in recent models shifted from US$9.00 to US$11.06, marking a sizeable uplift in the central price target. Analysts link these updated targets to new PermeaDerm-I data, RECELL usage trends, reimbursement developments and changes to the Stedical agreements, as they reassess how AVITA Medical might scale its burn care portfolio. As you read on, you will see how these moving targets fit into the broader narrative and what to watch to stay...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By